HRP20070267T3 - Azabicyclic heterocycles as cannabinoid receptor modulators - Google Patents
Azabicyclic heterocycles as cannabinoid receptor modulatorsInfo
- Publication number
- HRP20070267T3 HRP20070267T3 HR20070267T HRP20070267T HRP20070267T3 HR P20070267 T3 HRP20070267 T3 HR P20070267T3 HR 20070267 T HR20070267 T HR 20070267T HR P20070267 T HRP20070267 T HR P20070267T HR P20070267 T3 HRP20070267 T3 HR P20070267T3
- Authority
- HR
- Croatia
- Prior art keywords
- group
- double bond
- nr8s
- heterocyclyl
- cycloalkyl
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title abstract 6
- 239000003520 cannabinoid receptor affecting agent Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53145103P | 2003-12-19 | 2003-12-19 | |
| US11/016,198 US7816357B2 (en) | 2003-12-19 | 2004-12-17 | Azabicyclic heterocycles as cannabinoid receptor modulators |
| PCT/US2004/042878 WO2005063762A1 (en) | 2003-12-19 | 2004-12-17 | Azabicyclic heterocycles as cannabinoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20070267T3 true HRP20070267T3 (en) | 2007-08-31 |
Family
ID=34742367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20070267T HRP20070267T3 (en) | 2003-12-19 | 2007-06-08 | Azabicyclic heterocycles as cannabinoid receptor modulators |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7816357B2 (ko) |
| EP (1) | EP1697371B1 (ko) |
| JP (1) | JP2007514770A (ko) |
| KR (1) | KR20060103265A (ko) |
| AT (1) | ATE360631T1 (ko) |
| AU (1) | AU2004309368A1 (ko) |
| BR (1) | BRPI0417820A (ko) |
| CA (1) | CA2550375A1 (ko) |
| CY (1) | CY1106679T1 (ko) |
| DE (1) | DE602004006166T2 (ko) |
| DK (1) | DK1697371T3 (ko) |
| ES (1) | ES2284081T3 (ko) |
| HK (1) | HK1095138A1 (ko) |
| HR (1) | HRP20070267T3 (ko) |
| IL (1) | IL176110A0 (ko) |
| IS (1) | IS8503A (ko) |
| NO (1) | NO20062691L (ko) |
| PL (1) | PL1697371T3 (ko) |
| PT (1) | PT1697371E (ko) |
| RU (1) | RU2006126123A (ko) |
| WO (1) | WO2005063762A1 (ko) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0417820A (pt) | 2003-12-19 | 2007-03-27 | Bristol Myers Squibb Co | heterociclos azabicìclicos como moduladores de receptor canabinóide |
| JP2008514718A (ja) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ |
| JP4926069B2 (ja) * | 2004-11-01 | 2012-05-09 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 肥満ならびに肥満関連疾患および障害の治療方法 |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| US7629342B2 (en) | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| WO2007055743A2 (en) * | 2005-11-01 | 2007-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
| AU2006322707B2 (en) | 2005-12-07 | 2011-09-15 | Sumitomo Chemical Company, Limited | Pyridazine compound and use thereof |
| US8022073B2 (en) | 2005-12-07 | 2011-09-20 | Sumitomo Chemical Company, Limited | Substituted pyridazine compounds and fungicidal uses thereof |
| EP1988883A1 (fr) * | 2006-02-17 | 2008-11-12 | Trimaran Limited | Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions |
| US20080027087A1 (en) * | 2006-02-21 | 2008-01-31 | Ampla Pharmaceuticals, Inc. | CB1 antagonists and inverse agonists |
| WO2008021666A2 (en) * | 2006-08-18 | 2008-02-21 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| WO2008066845A2 (en) * | 2006-11-28 | 2008-06-05 | Ampla Pharmaceuticals Inc. | Treatment of metabolic syndrome with norfluoxetine |
| EP2094705B1 (en) | 2006-12-14 | 2012-04-18 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
| FR2910001B1 (fr) | 2006-12-18 | 2009-03-20 | Sod Conseils Rech Applic | Derives d'imidazo, pyrimido et diazepine pyrimidine-dione et leur utilisation comme medicament |
| AR064962A1 (es) * | 2007-01-22 | 2009-05-06 | Syngenta Participations Ag | Derivados de piridazina utiles como fungicidas |
| JP2008222603A (ja) * | 2007-03-09 | 2008-09-25 | Institute Of Physical & Chemical Research | 神経変性疾患の予防・治療剤 |
| EP3788877A1 (en) * | 2007-04-11 | 2021-03-10 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US20160331729A9 (en) * | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| DE102008000872A1 (de) | 2007-04-11 | 2008-11-13 | Basf Se | Fungizide Pyridazine, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung von Schadpilzen sowie sie enthaltende Mittel |
| ES2439255T3 (es) * | 2007-06-21 | 2014-01-22 | Cara Therapeutics, Inc. | Imidazoheterociclos sustituidos |
| US20090036426A1 (en) * | 2007-07-30 | 2009-02-05 | Ampla Pharmaceuticals Inc. | CB1 antagonists and inverse agonists |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| BRPI0722276A2 (pt) * | 2007-11-14 | 2014-04-22 | Amylin Pharmaceuticals Inc | Métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
| WO2010079241A1 (es) * | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| JP2013538215A (ja) | 2010-08-31 | 2013-10-10 | エスエヌユー アールアンドディービー ファウンデーション | ＰＰＡＲδアゴニストの胎児再プログラミング用途 |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2012142388A2 (en) * | 2011-04-15 | 2012-10-18 | New York University | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders |
| JP5437525B1 (ja) | 2012-12-28 | 2014-03-12 | 株式会社ナード研究所 | チロシン誘導体およびチロシン誘導体の製造方法 |
| JP6449235B2 (ja) | 2013-03-27 | 2019-01-09 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 治療に対する応答性を予測するための遺伝マーカー |
| RS57533B1 (sr) * | 2014-01-29 | 2018-10-31 | Ucb Biopharma Sprl | Heteroaril amidi kao inhibitori proteinske agregacije |
| KR102456013B1 (ko) | 2014-07-30 | 2022-10-18 | 에프. 호프만-라 로슈 아게 | 고밀도 지질단백질(hdl)-상승 제제 또는 hdl-모방 제제에 의한 치료법에 대한 반응성을 예측하기 위한 유전 표지 |
| US11434291B2 (en) | 2019-05-14 | 2022-09-06 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3994898A (en) * | 1975-10-16 | 1976-11-30 | E. R. Squibb & Sons, Inc. | 1,2,4-Triazolo (4,3-b) pyridazin-3-ones |
| IT1164198B (it) * | 1983-04-28 | 1987-04-08 | Isf Spa | Preparazione di un derivato piridazinico farmacologicamente attivo |
| JPS61106576A (ja) | 1984-10-31 | 1986-05-24 | Nippon Soda Co Ltd | トリアゾロピリダジン−３−オン誘導体及び製造方法 |
| BR9710729A (pt) | 1996-07-25 | 1999-08-17 | Merck Sharp & Dohme | Composto composi-Æo farmac-utica utiliza-Æo de um composto e processo para o tratamento e/ou a preven-Æo da ansiedade e de convuls{es para a triagem de compostos ansioliticos nÆo-sedativos e para a prepara-Æo de um composto |
| WO2000020417A1 (fr) | 1998-10-06 | 2000-04-13 | Takeda Chemical Industries, Ltd. | Composes de pyridazine condenses, leur procede de preparation et leur utilisation |
| AU2001234958A1 (en) | 2000-02-11 | 2001-08-20 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
| GB0107751D0 (en) * | 2001-03-28 | 2001-05-16 | Pfizer Ltd | Pharmaceutically active compounds |
| WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| JP2005519927A (ja) * | 2002-02-07 | 2005-07-07 | ファイザー・インク | 多嚢胞性卵巣症候群の処置における、シルデナフィル如きｐｄｅ５インヒビターの使用 |
| CA2478389A1 (en) * | 2002-03-25 | 2003-10-09 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| WO2004074259A1 (en) | 2003-02-19 | 2004-09-02 | Neurogen Corporation | Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds |
| TW200528455A (en) | 2003-12-19 | 2005-09-01 | Bristol Myers Squibb Co | Azabicyclic heterocycles as cannabinoid receptor modulators |
| BRPI0417820A (pt) | 2003-12-19 | 2007-03-27 | Bristol Myers Squibb Co | heterociclos azabicìclicos como moduladores de receptor canabinóide |
-
2004
- 2004-12-17 BR BRPI0417820-3A patent/BRPI0417820A/pt not_active IP Right Cessation
- 2004-12-17 AT AT04815007T patent/ATE360631T1/de not_active IP Right Cessation
- 2004-12-17 RU RU2006126123/04A patent/RU2006126123A/ru not_active Application Discontinuation
- 2004-12-17 KR KR1020067011999A patent/KR20060103265A/ko not_active Application Discontinuation
- 2004-12-17 US US11/016,198 patent/US7816357B2/en active Active
- 2004-12-17 ES ES04815007T patent/ES2284081T3/es active Active
- 2004-12-17 WO PCT/US2004/042878 patent/WO2005063762A1/en active Application Filing
- 2004-12-17 EP EP04815007A patent/EP1697371B1/en active Active
- 2004-12-17 JP JP2006545567A patent/JP2007514770A/ja active Pending
- 2004-12-17 DK DK04815007T patent/DK1697371T3/da active
- 2004-12-17 PT PT04815007T patent/PT1697371E/pt unknown
- 2004-12-17 DE DE602004006166T patent/DE602004006166T2/de not_active Expired - Fee Related
- 2004-12-17 PL PL04815007T patent/PL1697371T3/pl unknown
- 2004-12-17 AU AU2004309368A patent/AU2004309368A1/en not_active Abandoned
- 2004-12-17 CA CA002550375A patent/CA2550375A1/en not_active Abandoned
-
2006
- 2006-06-04 IL IL176110A patent/IL176110A0/en unknown
- 2006-06-08 IS IS8503A patent/IS8503A/xx unknown
- 2006-06-12 NO NO20062691A patent/NO20062691L/no not_active Application Discontinuation
-
2007
- 2007-02-16 HK HK07101918A patent/HK1095138A1/xx not_active IP Right Cessation
- 2007-06-08 HR HR20070267T patent/HRP20070267T3/xx unknown
- 2007-06-26 CY CY20071100845T patent/CY1106679T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1697371T3 (da) | 2007-09-17 |
| PT1697371E (pt) | 2007-08-03 |
| AU2004309368A1 (en) | 2005-07-14 |
| CA2550375A1 (en) | 2005-07-14 |
| RU2006126123A (ru) | 2008-01-27 |
| DE602004006166D1 (de) | 2007-06-06 |
| PL1697371T3 (pl) | 2007-09-28 |
| US7816357B2 (en) | 2010-10-19 |
| NO20062691L (no) | 2006-09-14 |
| CY1106679T1 (el) | 2012-05-23 |
| ATE360631T1 (de) | 2007-05-15 |
| JP2007514770A (ja) | 2007-06-07 |
| DE602004006166T2 (de) | 2008-01-10 |
| KR20060103265A (ko) | 2006-09-28 |
| EP1697371B1 (en) | 2007-04-25 |
| HK1095138A1 (en) | 2007-04-27 |
| IS8503A (is) | 2006-06-08 |
| EP1697371A1 (en) | 2006-09-06 |
| US20050171110A1 (en) | 2005-08-04 |
| BRPI0417820A (pt) | 2007-03-27 |
| ES2284081T3 (es) | 2007-11-01 |
| IL176110A0 (en) | 2006-10-05 |
| WO2005063762A1 (en) | 2005-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20070267T3 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
| HRP20070241T3 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
| AR047063A1 (es) | Heterociclos azabiciclicos como moduladores de receptor canabinoide | |
| EP1361220A4 (en) | CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM | |
| RS52953B (en) | PYRIDOPINIDINONSKI INHIBITORI PI3 KALFA | |
| NO20004778L (no) | Amidderivater og nociceptin antagonister | |
| WO2003037862A1 (fr) | Derives amide, et medicaments correspondants | |
| CA2401711A1 (en) | Cyclic amide derivatives | |
| EP1156045A4 (en) | AMID DERIVATIVES AND DRUG COMPOSITIONS | |
| ATE503746T1 (de) | Neue imidazolidinderivate | |
| UA72917C2 (en) | Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor | |
| IL192605A0 (en) | 1,2-dihydropyridin-2-one derivatives and pharmaceutical compositions containing the same | |
| AR014448A1 (es) | Compuesto de alanina, una composicion farmaceutica, uso del compuesto y proceso para la preparacion del compuesto | |
| HUP0002461A2 (hu) | Triciklusos benzotiepin- vagy benzoxepinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| BRPI0707491B8 (pt) | compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas | |
| WO2002026706A3 (en) | 17-beta-hydroxysteroid dehydrogenase-ii inhibitors | |
| YU68102A (sh) | Derivati karboksilne kiseline kao ip antagonisti | |
| AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
| AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
| HRP20041030B1 (hr) | Derivati benzoksazina kao regulatori 5-ht6 i njihova upotreba | |
| DE60024471D1 (de) | Benzopyran derivate | |
| ATE271868T1 (de) | Neue cathechole als antimikrobielle mittel | |
| AU2888892A (en) | 3-ureido-benzodiazepinones useful as antagonists of cck or of gastrine | |
| DK0874841T3 (da) | 1-Benzensulfonylpyrrolidin-derivater som antagonister af bradykinin-receptoren | |
| WO2002004416A3 (en) | Lactam metalloprotease inhibitors |